- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cutaneous T-Cell Lymphoma (CTCL)
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1116KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 68KB)
Mogamulizumab – November 2020
Mogamulizumab: Solution concentrate for I.V. infusion 20 mg in 5 mL; Poteligeo®
Last updated
5 March 2021